Ingalls & Snyder LLC Has $2.27 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Ingalls & Snyder LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 5.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,105 shares of the company’s stock after selling 740 shares during the period. Ingalls & Snyder LLC’s holdings in Zoetis were worth $2,272,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Lafayette Investments Inc. increased its position in Zoetis by 27.4% during the second quarter. Lafayette Investments Inc. now owns 1,640 shares of the company’s stock worth $284,000 after buying an additional 353 shares during the last quarter. Watershed Private Wealth LLC acquired a new position in Zoetis during the second quarter worth $302,000. IFG Advisory LLC acquired a new position in Zoetis during the second quarter worth $241,000. Concurrent Investment Advisors LLC increased its position in Zoetis by 20.0% during the second quarter. Concurrent Investment Advisors LLC now owns 9,039 shares of the company’s stock worth $1,567,000 after buying an additional 1,507 shares during the last quarter. Finally, Legacy Advisors LLC increased its position in Zoetis by 29.4% during the second quarter. Legacy Advisors LLC now owns 14,910 shares of the company’s stock worth $2,585,000 after buying an additional 3,392 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on ZTS shares. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. The Goldman Sachs Group lowered their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, HSBC reduced their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $217.11.

View Our Latest Report on Zoetis

Zoetis Trading Up 0.3 %

NYSE ZTS opened at $183.49 on Friday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $83.13 billion, a PE ratio of 35.35, a P/E/G ratio of 2.81 and a beta of 0.86. The stock has a 50-day simple moving average of $179.83 and a 200 day simple moving average of $174.54.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the firm earned $1.41 earnings per share. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. Research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read more

Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.